Anti-cholesterol antibodies in human sera

Autoimmunity Reviews

Volumn 2, Issue 5, 2003, Pages 272-277

  Horváth, Anna ^a   Bíró, Adrienn ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anti cholesterol antibodies; Atherosclerosis; Serum cholesterol

Indexed keywords

AUTOANTIBODY; CHOLESTEROL ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DRUG EFFECT; HUMAN; IMMUNE SYSTEM; ISCHEMIC HEART DISEASE; PERIPHERAL NEUROPATHY; REVIEW; VIRUS INFECTION;

ANIMALS; ARTERIOSCLEROSIS; AUTOANTIBODIES; CHOLESTEROL; HUMANS;

EID: 17944392022     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00034-X     Document Type: Review

References (29)

1. Sachs H., Klopstock A. Die serologische differenzierung von lecithin und cholesterin. Biochem Z. 159:1925;491-501.
2. Landsteiner K. The specificity of serological reactions. 1945;Harvard University Press, Cambridge. revised ed.
3. Sato J., Fukunda T., Hara I. Preparation of anti-eticholenic acid antiserum and anti-cholesterol succinate antiserum and their cross reactivities. J Exp Med. 46:(4):1976;213-221.
4. Alving C.R., Swartz G.M., Wassef N.M., et al. Immunisation with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolaemia and plaque formation. J Lab Clin Med. 127:(1):1996;40-49.
5. Dijkstra J., Swartz G.M., Raney J.J., et al. Interactions of anti-cholesterol antibodies with human lipoproteins. J Immunol. 157:1996;2006-2013.
6. Swartz G.M. Jr., Gentry M.K., Amende L.M., Blanchette-Mackie E.J., Alving C.R. Antibodies to cholesterol. Proc Natl Acad Sci USA. 85:(6):1988;1902-1906.
7. Horváth I., Szende B., Horváth A., Kocsis I., Horváth A. Influence of cholesterol liposome immunisation and immunostimulation on rabbits atherosclerosis induced by a high cholesterol diet. Med Sci Monit. 4:(3):1998;403-407.
8. Alving C.R., Swartz G.M., Wassef N.M., et al. Naturally occurring autoantibodies to cholesterol in humans. Biochem Soc Trans. 629:1989;637-639.
9. Horváth I., Puskás É., Horváth A., Balázs É., Horváth A. Autoantitest, vagy immunológiai védekezés koleszterinnel szemben? Orvosi Hetilap. 135:(18):1994;965-968.
10. Avila J.L., Rojas M., Avila A. Cholesterol sulphate-reacting autoantibodies are specifically increased in chronic Chagasic patients. Clin Exp Immunol. 103:1996;40-46.
11. Horváth A., Füst G., Horváth I., et al. Anti-cholesterol antibody (ACHA) levels in patients with different atherosclerotic vascular diseases. Characterization of human ACHA. Atherosclerosis. 156:2001;185-192.
12. Alving C.R., Swartz G.M. Jr. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Immunology. 10:(5):1991;441-453.
13. Alving C.R., Swartz G.M. Jr., Wassef N.M. Vaccination against cholesterol: immunologic modulation of diet induced hypercholesterolaemia and atherosclerosis in rabbits. Clin Immunother. 3:1995;409-414.
14. Warlow C.P. Epidemiology of stroke. Lancet. 352:(Suppl III):1998;1-4.
15. Kramer J., Harcos P., Duba J., Prohászka Z., Császá r A., Füst G. Differences in C4B allele frequencies between patients with cerebrovascular disease. Mol Immunol. 35:(6-7):1998;356.
16. Veres A., Füst G., McQueen M., et al. Relationship of anti-60 kDa Heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation. 106:2002;2775-2780.
17. Torzewski J., Bowyer D.E., Waltenberger J., Fitzsimmons C. Processes in atherogenesis: complement activation. Atherosclerosis. 132:(2):1997;131-138.
18. Vincent S., Gerlier D., Manie S.N. Measles virus assembly within membrane rafts. J Virol. 74:2000;9911-9915.
19. Scheiffele P., Rietveld A., Wilk T., Simons K. Influenza virus select ordered lipid domains during budding from the plasma membrane. J Biol Chem. 274:1999;2038-2044.
20. Liao Z., Cimakasky L.M., Hampton R., Nguyen D.H., Hildreth J.E. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses. 17:2001;1009-1019.
21. Nguyen D.H., Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol. 74:2000;3264-3272.
22. Swindells S. Metabolic complications of HIV disease. Nurs Pract. 24:1999;125-129.
23. Kruth H.S., Ifrim I., Chang J., Addadi L., Perl-Treves D., Zhang W.Y. Monoclonal antibody detection of plasma membrane cholesterol microdomains responsive to cholesterol trafficking. J Lipid Res. 42:2001;1492-1500.
24. Campbell S.M., Crowe S.M., Mak J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol. 2001;217-227.
25. Horváth A., Bánhegyi D., Bíró A., et al. High level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. Immunobiology. 2001;756-768.
26. Bíró A., Horváth A., Varga L., et al. Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN-α-2b treatment. Immunobiol. 207:2003;1-8.
27. Berthold H.K., Parhofer K.G., Ritter M.M., et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med. 246:1999;567.
28. Pirich C., Efthimiou Y., O'Grady J., Zielinski C., Sinzinger H. Apoliporotein A and biological half-life of prostaglandin I2 in HIV-1 infection. Thromb Res. 81:1996;213.
29. Serfaty L., Andreani T., Giral P., Carbonell N., Chazouilléres O., Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 34:2001;428.